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ORIGINAL ARTICLE
Early Disease Activity or Clinical Response as
Predictors of Long-Term Outcomes With
Certolizumab Pegol in Axial Spondyloarthritis or
Psoriatic Arthritis
D. VAN DER HEIJDE,1 A. DEODHAR,2 R. FLEISCHMANN,3 P. J. MEASE,4 M. RUDWALEIT,5
T. NURMINEN,6 AND O. DAVIES7
Objective. Early identification of patients unlikely to achieve good long-term disease control with anti–tumor necrosis factor
therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat-to-target rec-
ommendations. Here we assess associations between disease activity or clinical response during the first 12 weeks of treat-
ment and attainment of treatment targets at week 48 in axial SpA and PsA patients receiving certolizumab pegol.
Methods. The relationship between disease activity or clinical response during the first 12 weeks of treatment and achieve-
ment of week-48 targets (for axial SpA: inactive disease based on Ankylosing Spondylitis Disease Activity Score [ASDAS]
using the C-reactive protein [CRP] level, or Bath Ankylosing Spondylitis Disease Activity Index <2 with normal CRP level;
and for PsA: minimal disease activity) was assessed post hoc using RAPID-axSpA and RAPID-PsA trial data.
Results. A clear relationship between disease activity from week 2 to 12 and achievement of week-48 treatment targets was
observed in both axial SpA and PsA populations. In axial SpA, week-48 ASDAS inactive disease was achieved by 0% of
patients (0 of 21) with ASDAS very high disease activity at week 12, compared to 68% of patients (34 of 50) with week-12
ASDAS inactive disease. For PsA, week-48 minimal disease activity was achieved by 0% of patients (0 of 26) with Disease
Activity Score in 28 joints (DAS28) using the CRP level >5.1 at week 12, compared to 73% of patients (57 of 78) with DAS28-
CRP <2.6. Similar results were observed regardless of the disease activity measure used. Clinical response at week 12 also pre-
dicted week-48 outcomes, though to a lesser extent than disease activity.
Conclusion. Using disease activity and the clinical response state during the first 12 weeks of certolizumab pegol treatment, it
was possible to identify a subset of axial SpA and PsA patients unlikely to achieve long-term treatment goals.
INTRODUCTION
Recent recommendations have been published to suggest
treatment targets for spondyloarthritis (SpA), including axial
SpA and psoriatic arthritis (PsA) (1). These recommenda-
tions state that a primary goal of treatment in these diseases
is to maximize the long-term health-related quality of life
and social participation of patients through the preservation
of function and prevention of structural damage (1). In
ClinicalTrials.gov identifiers: NCT01087762 (RAPID-
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addition, the recommendations state that the treatment tar-
gets should assess laboratory measures of inflammation,
such as C-reactive protein (CRP) levels, alongside clinical
outcomes, or that composite outcomes should be used that
incorporate both. The treatment targets recommended were
clinical remission or inactive disease (1). The treat-to-target
recommendations in SpA suggest allowing a maximum of 6
months for reaching the treatment target, but that therapy
should be adapted at 3 months if there has been no signifi-
cant reduction in disease activity by this point (1).
In line with these recommendations, the early identifica-
tion of patients unlikely to achieve treatment targets (negative
predictability) may help avoid unnecessary exposure to treat-
ment, potentially increase cost-effectiveness, and improve
the chance of patients achieving long-term goals. To date,
negative predictability has not been explored as a primary
objective in any analyses in patients with axial SpA or PsA,
where axial SpA includes both ankylosing spondylitis and
nonradiographic axial SpA patients, referring to the presence
or absence of sacroiliac joint changes on radiographs (2). Here
we investigated whether the lack of early response or lack of
achievement of important disease activity thresholds over
the first 12 weeks of treatment could be used to identify
patients with axial SpA or PsA receiving certolizumab pegol
(CZP) treatment who were unlikely to attain the desired treat-
ment targets at week 48.
PATIENTS AND METHODS
Patients. Analyses were carried out on CZP-treated
patients from the RAPID-axSpA (3) and RAPID-PsA (4) trials.
Both trials were phase 3, multicenter, randomized trials that
were double-blind and placebo-controlled to week 24, dose-
blind to week 48, and open-label to week 204 for RAPID-
axSpA or week 216 for RAPID-PsA. The analyses reported
here use data up to week 48.
In RAPID-axSpA, eligible patients had active axial SpA
(Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]
$4 and spinal pain $4) of $3 months’ duration, had to meet
the Assessment of SpondyloArthritis international Society
classification criteria for axial SpA (5,6), and had failed treat-
ment with, or been resistant to, $1 nonsteroidal antiinflamma-
tory drug. Eligible patients were stratified at randomization
based on the modified New York criteria. The primary clinical
end point of RAPID-axSpA (3) and long-term safety and effi-
cacy data (to week 96) (7) have been reported elsewhere.
In RAPID-PsA, eligible patients had PsA as defined by the
Classification Criteria for Psoriatic Arthritis (8), had active
disease ($3 tender joints and $3 swollen joints, and either
erythrocyte sedimentation rate [ESR] $28 mm/hour or CRP
level .7.9 mg/liter) of $6 months’ duration, and had failed
treatment with, or been resistant to, $1 disease-modifying
antirheumatic drug. The primary clinical (4) and radiographic
(9) end points of RAPID-PsA have been reported elsewhere,
as have long-term (to week 96) (10) outcomes from this trial.
Evaluations. The relationship between disease activity or
clinical response during the first 12 weeks of CZP treatment
and achievement of a treatment target at week 48 was
assessed. Each analysis considered 1 treatment target and 1
predictor, which are described below and shown in Table 1.
Treatment targets: axial SpA. To assess predictability,
the achievement of disease activity targets at week 48 was
considered. The treatment targets selected were among those
suggested in the treat-to-target recommendations (1). For
axial SpA, the treatment targets chosen were Ankylosing
Spondylitis Disease Activity Score (ASDAS) inactive disease
(ASDAS ,1.3) and BASDAI ,2 with normal CRP level
(#7.9 mg/liter). ASDAS includes both disease activity com-
ponents and laboratory investigations of serologic inflamma-
tory response (CRP level). As BASDAI does not contain a
CRP component, BASDAI plus normal CRP level (at or
below the upper limit of normal of #7.9 mg/liter) were used
as a treatment target, rather than BASDAI alone, as suggested
in the treat-to-target recommendations (1).
Treatment targets: PsA. For PsA, minimal disease activ-
ity (MDA) was selected as the treatment target. Achievement
of MDA (11) is defined as the achievement of 5 of 7 criteria:
tender joint count #1, swollen joint count #1, psoriasis area
and severity index #1 or body surface area #3, pain visual
analog scale (VAS) #15, patient’s global assessment of dis-
ease activity VAS #20, health assessment questionnaire
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#0.5, and tender entheseal points #1 in the Leeds Enthesitis
Index (12).
Predictors: disease activity. In order to predict the
absence of reaching the treatment target at week 48, a num-
ber of possible predictors were considered at early time
points (up to week 12), as summarized in Table 1. For axial
SpA, ASDAS disease activity was defined using validated
(13) cutoff values for inactive, moderate, high, or very high
disease activity, while BASDAI disease activity was defined
using unvalidated cutoff values for low, moderate, high or
very high disease activity. The unvalidated cutoff values for
BASDAI disease activity are similar to those previously
described in the literature (14,15).
For PsA, in the absence of well-accepted Disease Activity
Score in 28 joints (DAS28) using the CRP level thresholds in
PsA patients, disease activity was defined using thresholds
validated for DAS28-ESR in rheumatoid arthritis (RA) (Table
1) (16). Although these thresholds have not been validated in
PsA, and they show poor performance in RA, these have
been selected due to the lack of a better alternative (17).
Predictors: clinical response. For axial SpA clinical
response, validated (13) ASDAS cutoff values and
unvalidated BASDAI cutoff values were used, as shown in
Table 1. Patient-reported outcomes were also considered to
assess clinical response. For axial SpA, the patient-
completed total back pain score (0–10 numerical rating scale)

















1) ,1.3, inactive disease
2) $1.3 to ,2.1, moderate
disease activity
3) $2.1 to #3.5, high disease
activity




1) $2.0, major improvement
2) 1.1 to ,2.0, clinically important
improvement (CII) but not
major improvement




Daily pain diary response:







1) ,2, low disease activity
2) $2 to ,4, moderate disease
activity
3) $4 to #6, high disease
activity





2) $2 to ,4













2) $2.6 to #3.2





2) .0.6 to 1.2
3) #0.6
PsARC response:
1) Improvement from baseline in
2 of 4 criteria, 1 of which must
be TJC or SJC, and no 1
point $30% worsening from
baseline in any of the measures
Patient assessment of arthritis
pain score MCID:
1) $10-point decrease from
baseline
* SpA 5 spondyloarthritis; ASDAS 5 Ankylosing Spondylitis Disease Activity Score; MCID 5 minimal clinically important difference; BASDAI 5 Bath
Ankylosing Spondylitis Disease Activity Index; CRP 5 C-reactive protein; ULN 5 upper limit of normal; PsA 5 psoriatic arthritis; MDA 5 minimal dis-
ease activity; DAS28-CRP 5 Disease Activity Score in 28 joints using the CRP; PsARC 5 Psoriatic Arthritis Response Criteria: TJC 5 tender joint count;
SJC 5 swollen joint count.
† Mean of total and nocturnal spinal pain measures used as baseline score, as the daily pain diary was completed from day 1.
‡ Unvalidated in PsA.
§ Unvalidated in PsA; validated in rheumatoid arthritis (16).
1032 van der Heijde et al
was used. This outcome was assessed at regular visits and
through a daily pain diary from day 0–28 of the trial (the same
question was used except that the recall period was modified
from “in the last week” for regular assessments to “during the
last 24 hours” for the daily pain diary). Clinical response was
defined as the achievement or lack of achievement of a mini-
mal clinically important difference (MCID) in pain score (18)
or a response in the patient daily pain diary (Table 1).
For PsA, the unvalidated DAS28-CRP clinical response
was defined using thresholds validated for DAS28-ESR in
RA (16), or as a Psoriatic Arthritis Response Criteria (PsARC)
response (19). The patient assessment of arthritis pain score
(by VAS) was also considered, with clinical response
defined as a pain score MCID (20) (Table 1).
Statistical analysis. Analyses were carried out on all
patients originally randomized to CZP at week 0 (200 mg
every 2 weeks and 400 mg every 4 weeks, doses combined).
For RAPID-axSpA, this analysis included 218 patients and
for RAPID-PsA 273 patients. Additional analyses were car-
ried out for the ankylosing spondylitis and nonradiographic
axial SpA subpopulations from the RAPID-axSpA trial.
Predictability analyses at a given week were based on all
patients continuing treatment at that week. Last observation
carried forward estimation was applied for intermittently
missing disease activity or clinical response assessments to
week 12 (i.e., for all predictors). For treatment targets, for
those patients withdrawing between the early disease activ-
ity or clinical response assessments and week 48, or other-
wise missing week 48 assessments, missing data were
imputed by last observation carried forward (ASDAS and
BASDAI-CRP) or nonresponder imputation (for MDA).
RESULTS
Disease activity as a predictor of treatment target
attainment. Disease activity in axial SpA, including
ankylosing spondylitis and nonradiographic axial SpA
patients. Baseline disease activity, when assessed using
either ASDAS or BASDAI, was not strongly associated with
the attainment of week 48 treatment targets. However, fol-
lowing treatment initiation, both ASDAS and BASDAI dis-
ease activity were strong predictors for the achievement or
lack of achievement of week-48 treatment targets, with dis-
ease activity as early as week 2 predicting longer-term out-
comes in patients treated with CZP.
ASDAS disease activity state at week 2 was associated
with the likelihood of achieving ASDAS inactive disease at
week 48, with 0% of patients (0 of 27) with ASDAS very
high disease activity at week 2 achieving ASDAS inactive
disease at week 48, compared to 71% of patients (22 of 31)
with ASDAS inactive disease at week 2 achieving ASDAS
inactive disease at week 48 (Figure 1). A trend of decreasing
Figure 1. Proportion of patients achieving disease activity targets at week 48 based on
classification of disease activity at baseline, week 2, week 8, and week 12. Values are the
number/total number (percentage). * 5 the number of axial spondyloarthritis (SpA)
patients at each visit: 218 at baseline, 217 at week 2, 215 at week 8, and 211 at week 12.
† 5 the number of psoriatic arthritis (PsA) patients at each visit: 272 at baseline, 270 at
week 2, 262 at week 8, and 256 at week 12. ASDAS 5 Ankylosing Spondylitis Disease
Activity Score; ID 5 inactive disease; MD 5 moderate disease; HD 5 high disease;
vHD 5 very high disease; BASDAI 5 Bath Ankylosing Spondylitis Disease Activity Index;
CRP 5 C-reactive protein; ULN 5 upper limit of normal; MDA 5 minimal disease activity;
DAS28 5 Disease Activity Score in 28 joints.
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achievement of ASDAS inactive disease was observed with
higher disease activity at week 2, from inactive disease
through to moderate, high, and very high disease activity. A
similar trend was observed at week 8 and week 12, although
fewer patients had high and very high disease activity, and
more patients had inactive disease at later time points.
A similar association between disease activity during the
first 12 weeks of therapy and achievement of treatment tar-
gets was observed when BASDAI was considered. Very high
disease activity (BASDAI .6) successfully predicted the
lack of attainment of the treatment target BASDAI ,2 and
CRP at or below the upper limit of normal (Figure 1). Disease
activity was a strong negative predictor for the achievement
of week-48 treatment targets across the ankylosing spondyli-
tis and nonradiographic axial SpA subpopulations (Figure
2A and 2B).
Sensitivity analyses were performed using nonresponder
imputation, rather than last observation carried forward. Only
3 fewer patients achieved ASDAS inactive disease when the
more conservative imputation method (nonresponder) was
used, and therefore a change in imputation methodology is
unlikely to have affected the outcomes of this analysis.
Disease activity in PsA. Higher DAS28-CRP was a strong
negative predictor for achievement of the treatment target in
PsA. A clear relationship between disease activity state at
week 2 and MDA at week 48 was observed, with 10% of
patients (5 of 52) with week 2 DAS28-CRP .5.1 achieving
week-48 MDA, compared with 68% of patients (17 of 25)
with DAS28-CRP ,2.6 at week 2 (Figure 1). As with axial
SpA, a trend was seen across the various levels of disease
activity, with a decreasing proportion of patients achieving
MDA in progressively higher disease activity states. This
trend was maintained to week 12, at which point more
patients had lower disease activity. At week 48, MDA was
achieved by 0% of patients (0 of 26) with week-12 DAS28-
CRP .5.1, compared to 73% of patients (57 of 78) with
week-12 DAS28-CRP ,2.6.
Clinical response predicts achievement of treatment
targets. Clinical response in axial SpA, including ankylos-
ing spondylitis and nonradiographic axial SpA patients. A
lack of early clinical response to CZP was also an effective
negative predictor of week-48 disease activity. In axial SpA,
only 7% of patients (3 of 45) with week 12 BASDAI improve-
ment ,1 achieved week-48 disease activity of BASDAI ,2
and CRP at or below the upper limit of normal (Figure 3).
When ASDAS inactive disease was used as the treatment
target, 18% of patients (12 of 65) with week-12 ASDAS less
than clinically important improvement achieved the treat-
ment target at week 48, compared to 47% of patients (39 of
83) with week-12 major improvement (Figure 3). A similar
trend was seen in the ankylosing spondylitis and nonradio-
graphic axial SpA subpopulations, whether using ASDAS or
BASDAI to define clinical response and treatment target (Fig-
ure 4A and 4B).
Lack of early improvement in pain score was also a nega-
tive predictor of achievement of week-48 treatment targets.
Just 12% of patients (9 of 74) not achieving a daily pain
response by day 7 went on to achieve ASDAS inactive dis-
ease at week 48, compared to 41% of patients (57 of 138)
achieving a daily pain response (Figure 3).
At week 12, 6% of patients (2 of 36) not achieving week-12
pain MCID went on to achieve week-48 ASDAS inactive dis-
ease, compared to 37% of patients (65 of 175) with pain
MCID. When BASDAI ,2 and CRP at or below the upper
limit of normal were considered as the treatment target, only
3% (1 of 36) of week-12 MCID nonresponders achieved the
week-48 treatment target (Figure 3).
Figure 2. Disease activity at week 12 successfully predicts lack of attainment of treatment targets. axSpA 5 axial spondyloarthritis;
AS 5 ankylosing spondylitis; nr 5 nonradiographic; PsA 5 psoriatic arthritis; minDA 5 minimal disease activity. See Figure 1 for other
definitions.
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Clinical response in PsA. Clinical response at week 12
was also associated with the likelihood of attaining treatment
targets at week 48 in PsA patients. At week 48, MDA was
achieved by only 12% of patients (6 of 50) with week-12
DAS28-CRP improvement from baseline #0.6, compared with
50% of patients (76 of 153) with week 12 DAS28-CRP
improvement from baseline .1.2. Similar results were seen
when using early PsARC response as a predictor, with fewer
week-12 PsARC nonresponders achieving week-48 MDA than
responders (Figure 3). At week 12, only 14% of patients (10 of
72) without week-12 pain MCID achieved week-48 MDA,
whereas 48% of patients (89 of 184) with week-12 pain MCID
went on to achieve MDA at week 48.
Maintained achievement or lack of achievement of
treatment targets. Treat-to-target recommendations empha-
size the importance of the maintenance of targets throughout
the disease course (1). To this end, a heat-map approach is
presented, where individual patient disease activity scores
are shown by visit, sorted according to their week-12 disease
activity score (Figure 5).
Figure 3. Likelihood of achieving disease activity targets at week 48 based on clinical response or
on achievement of patient-reported outcome responses at early time points. Values are the number/
total number (percentage). * 5 the number of axial spondyloarthritis (SpA) patients at each visit:
218 at baseline, 217 at week 2, 215 at week 8, and 211 at week 12. † 5 the number of PsA patients at
each visit: 272 at baseline, 270 at week 2, 262 at week 8, and 256 at week 12. MI 5 major improve-
ment; CII 5 clinically important improvement; MCID 5 minimal clinically important difference;
PsARC 5 Psoriatic Arthritis Response Criteria. See Figure 1 for other definitions.
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This heat map shows that the level of disease activity
achieved at week 12 is maintained relatively consistently
over time. However, some variation in disease activity is
observed between visits, with some patients experiencing
worsening disease activity and some seeing greater improve-
ments. This variability likely represents the natural fluctuat-
ing course of these inflammatory diseases.
DISCUSSION
The prediction of response in axial SpA and PsA patients
has not been studied extensively. The majority of work in
the literature has focused on prediction of response in
patients with ankylosing spondylitis, PsA, RA, or psoriasis,
and has focused on the use of baseline characteristics to
identify patients likely to achieve a good therapeutic
response (21–25), or else the use of early treatment response
to predict those patients likely to achieve treatment targets at
later time points (positive predictability) (26–30). These
studies have consistently found that long-term clinical
improvements are predicted by raised inflammatory markers
(such as CRP level) at baseline, and by an early clinical
response to treatment. Other factors predictive of long-term
improvements in some of these studies were better function
(lower Bath Ankylosing Spondylitis Functional Index score),
lower enthesitis score, younger age, HLA–B27 positivity,
male sex and anti–tumor necrosis factor naivety at baseline
in ankylosing spondylitis (22–25), and baseline health
assessment questionnaire in PsA (21).
The use of baseline characteristics to predict those patients
likely to respond well to a given therapy can be used to tailor
treatments to specific patients, thus increasing the likelihood
of a patient responding well to their initial treatment and
reducing the need to switch therapies. Positive prediction
based on early response provides clinicians with reassurance
when continuing a patient on their current treatment. Com-
plementary to these ideas is the concept of negative predic-
tion, which can inform a clinician whether or not to
consider stopping treatment in a patient who is not
responding or who is having a suboptimal response to
therapy.
The concept of negative predictability has previously been
demonstrated in RA patients treated with CZP (31,32). In
RA, clinically applicable models were used to successfully
identify which patients may benefit from switching therapy
after 12 weeks of CZP treatment. These patients were pre-
dicted to be nonresponders at week 52 (patients with a very
low likelihood of achieving low disease activity) with a high
degree of specificity, based on the improvement in their dis-
ease activity level at week 12 (DAS28 improvement from
baseline) (31,32). Here we demonstrate that this approach is
also applicable to axial SpA and PsA patients treated with
CZP. The axial SpA data reported here demonstrate that the
prediction of long-term nonresponse (based on remission or
low disease activity) was independent of the presence of
radiographic sacroiliitis and provides further evidence that
the use of treat-to-target methods can be applied across the
spectrum of axial SpA patients, inclusive of both the anky-
losing spondylitis and nonradiographic axial SpA subpopu-
lations. Furthermore, these concepts were applicable when
using either clinician-rated outcomes or patient self-reported
outcomes as the predictor.
In this article we present individual patient data, which
show that very few patients with high or very high disease
activity at week 12 had moderate or inactive disease at any
Figure 4. Clinical response at week 12 predicts lack of attainment of treatment targets moderately well. axSpA 5 axial spondyloarthri-
tis; AS 5 ankylosing spondylitis; nr 5 nonradiographic; MI 5 major improvement; CII 5 clinically important improvement;
PsA 5 psoriatic arthritis; minDA 5 minimal disease activity; PsARC 5 Psoriatic Arthritis Response Criteria. See Figure 1 for other
definitions.
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time point thereafter, and that the majority of patients with
inactive disease at week 12 maintained this result through-
out. This finding suggests that following initial CZP treat-
ment, disease activity states are maintained over time, thus
lending credibility to the prediction model used here, in
which only one future time point is considered.
The analyses reported here have a number of limitations.
One such limitation is the lack of validated thresholds for
DAS28-CRP and BASDAI. Although the DAS28-CRP is not
validated in PsA, most patients in the study had polyarticu-
lar disease and therefore DAS28-CRP was felt to be the most
appropriate measure in the absence of another well-accepted
and validated measure in PsA to assess disease activity,
although there is also debate about the thresholds of remis-
sion and low disease activity in RA. A second potential limi-
tation in these analyses is the use of last observation carried
forward imputation for axial SpA analyses for the ASDAS
and BASDAI outcome measures, as has been previously used
when reporting these outcomes from the RAPID-axSpA trial
(7). However, the number of patients achieving ASDAS inac-
tive disease remained similar when an alternative, more con-
servative imputation method (nonresponder) was used. As
the number of patients affected was so low, the outcomes of
this investigation were unlikely to be impacted by a change
in imputation methodology. A further limitation is the use of
data from clinical trials, which may mean that these results
are not representative of the wider axial SpA and PsA patient
populations, as clinical trial populations tend to have worse
disease activity and fewer comorbidities than the general
patient population. Finally, the results are restricted by the
limited number of patients in the ankylosing spondylitis and
nonradiographic axial SpA subpopulations.
Here we have shown that by using disease activity state or, to
a lesser extent, clinical response during the first 12 weeks of
CZP treatment, we were able to identify a subset of axial SpA
or PsA patients who are unlikely to achieve long-term treat-
ment goals. For the treating clinician in practice, discontinua-
tion of CZP treatment should be considered in axial SpA
patients with ASDAS very high disease activity or BASDAI .6
after 12 weeks of CZP treatment, as these patients are very
unlikely to achieve treatment targets (ASDAS inactive disease
or BASDAI ,2 and normal CRP) at later time points. Moreover,
patients at week 12 who still have ASDAS high disease activity
or BASDAI .4 have only a small chance to reach the treatment
target and stopping treatment should be considered. Similarly,
for PsA patients with DAS28-CRP .5.1 after 12 weeks of CZP
treatment, careful consideration should be given before con-
tinuing treatment with CZP, as these patients are unlikely to go
on to achieve MDA. Also for patients with DAS28-CRP .3.2 to
5.1, the risk/benefit of continuation should be carefully consid-
ered, as reaching the target is achieved by a small percentage of
patients. Although early clinical response was not as strong a
negative predictor for the lack of achievement of long-term
treatment targets, these results support discontinuation of CZP
treatment after 12 weeks in axial SpA patients with ,1 unit
improvement in BASDAI at week 12, as they are also unlikely
to achieve later treatment targets. This negative prediction
approach may enable physicians adopting a treat-to-target strat-
egy to determine early on when to change therapy in patients
not responding to CZP.
ACKNOWLEDGMENTS
The authors thank the patients and their caregivers in addi-
tion to the investigators and their teams who contributed to
this study. The authors also thank Joseph Burgon, PhD, and
Sana Eljamel, MBChB, from Costello Medical Consulting
(Cambridge, UK), for medical writing and editorial assistance
Figure 5. Heat map representing Ankylosing Spondylitis Dis-
ease Activity Score (ASDAS) disease activity at each visit
grouped by patients’ week-12 ASDAS category and sorted by
baseline ASDAS.
Axial SpA and PsA Predictability 1037
in preparing this article for publication based on the authors’
input and direction.
ROLE OF THE STUDY SPONSOR
UCB Pharma sponsored the study and the development of the
manuscript and reviewed the text to ensure that from the UCB
perspective, the data presented in the publication are scientifically,
technically, and medically supportable, do not contain any informa-
tion that has the potential to damage the intellectual property of
UCB, and that the publication complies with applicable laws,
regulations, guidelines, and good industry practice. Publication of
this article was contingent upon approval by UCB Pharma.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it criti-
cally for important intellectual content, and all authors approved the
final version to be submitted for publication. Dr. van der Heijde had
full access to all of the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis.
Study conception and design. Deodhar, Nurminen, Davies.
Acquisition of data. van der Heijde, Deodhar, Fleischmann, Mease,
Rudwaleit.
Analysis and interpretation of data. van der Heijde, Deodhar,
Fleischmann, Mease, Rudwaleit, Nurminen, Davies.
REFERENCES
1. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O,
Helliwell P, et al. Treating spondyloarthritis, including
ankylosing spondylitis and psoriatic arthritis, to target: rec-
ommendations of an international task force. Ann Rheum
Dis 2014;73:6–16.
2. Sieper J, van der Heijde D. Nonradiographic axial spondylo-
arthritis: new definition of an old disease? Arthritis Rheum
2013;65:543–51.
3. Landewe R, Braun J, Deodhar A, Dougados M,
Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab
pegol on signs and symptoms of axial spondyloarthritis
including ankylosing spondylitis: 24-week results of a
double-blind randomised placebo-controlled phase 3 study.
Ann Rheum Dis 2014;73:39–47.
4. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J,
Khraishi M, Kielar D, et al. Effect of certolizumab pegol on
signs and symptoms in patients with psoriatic arthritis: 24-
week results of a phase 3 double-blind randomised placebo-
controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48–
55.
5. Rudwaleit M, Landewe R, van der Heijde D, Listing J,
Brandt J, Braun J, et al. The development of Assessment of
SpondyloArthritis international Society classification crite-
ria for axial spondyloarthritis (part I): classification of paper
patients by expert opinion including uncertainty appraisal.
Ann Rheum Dis 2009;68:770–6.
6. Rudwaleit M, van der Heijde D, Landewe R, Listing J,
Akkoc N, Brandt J, et al. The development of Assessment of
SpondyloArthritis international Society classification crite-
ria for axial spondyloarthritis (part II): validation and final
selection. Ann Rheum Dis 2009;68:777–83.
7. Sieper J, Landewe R, Rudwaleit M, van der Heijde D,
Dougados M, Mease PJ, et al. Effect of certolizumab pegol
over ninety-six weeks in patients with axial spondyloarthri-
tis: results from a phase III randomized trial. Arthritis
Rheumatol 2015;67:668–77.
8. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P,
Mielants H. Classification criteria for psoriatic arthritis:
development of new criteria from a large international
study. Arthritis Rheum 2006;54:2665–73.
9. Van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar
A, Kielar D, Woltering F, et al. Effect of different imputation
approaches on the evaluation of radiographic progression in
patients with psoriatic arthritis: results of the RAPID-PsA
24-week phase III double-blind randomised placebo-
controlled study of certolizumab pegol. Ann Rheum Dis
2014;73:233–7.
10. Mease P, Deodhar A, Fleischmann R, Wollenhaupt J,
Gladman D, Leszczynski P, et al. Effect of certolizumab
pegol over 96 weeks in patients with psoriatic arthritis with
and without prior antitumour necrosis factor exposure.
RMD Open 2015;1:e000119.
11. Coates LC, Fransen J, Helliwell PS. Defining minimal dis-
ease activity in psoriatic arthritis: a proposed objective tar-
get for treatment. Ann Rheum Dis 2010;69:48–53.
12. Healy PJ, Helliwell PS. Measuring clinical enthesitis in pso-
riatic arthritis: assessment of existing measures and devel-
opment of an instrument specific to psoriatic arthritis.
Arthritis Rheum 2008;59:686–91.
13. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D,
et al. Ankylosing Spondylitis Disease Activity Score
(ASDAS): defining cut-off values for disease activity states
and improvement scores. Ann Rheum Dis 2011;70:47–53.
14. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C,
Dougados M, van den Bosch F, et al. Higher disease activity
leads to more structural damage in the spine in ankylosing
spondylitis: 12-year longitudinal data from the OASIS
cohort. Ann Rheum Dis 2014;73:1455–61.
15. Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J.
Reaching a status of low disease activity spontaneously over
two year follow-up in active patients with non-radiographic
axial spondyloarthritis in comparison to ankylosing spondy-
litis not treated with TNF blockers. Ann Rheum Dis 2014;73
Suppl 2:422–3.
16. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of
rheumatoid arthritis improvement criteria that include sim-
plified joint counts. Arthritis Rheum 1998;41:1845–50.
17. Fleischmann R, van der Heijde D, Koenig AS, Pedersen R,
Szumski A, Marshall L, et al. How much does Disease
Activity Score in 28 joints ESR and CRP calculations under-
estimate disease activity compared with the Simplified Dis-
ease Activity Index? Ann Rheum Dis 2015;74:1132–7.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff
M, Fried B, et al. The American College of Rheumatology
preliminary core set of disease activity measures for rheu-
matoid arthritis clinical trials. Arthritis Rheum 1993;36:
729–40.
19. Mease PJ. Measures of psoriatic arthritis: Tender and Swol-
len Joint Assessment, Psoriasis Area and Severity Index
(PASI), Nail Psoriasis Severity Index (NAPSI), Modified
Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle
Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spon-
dyloarthritis Research Consortium of Canada (SPARCC),
Maastricht Ankylosing Spondylitis Enthesis Score (MASES),
Leeds Dactylitis Index (LDI), Patient Global for Psoriatic
Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic
Arthritis Quality of Life (PsAQOL), Functional Assessment
of Chronic Illness Therapy–Fatigue (FACIT-F), Psoriatic
Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint
Activity Index (PsAJAI), Disease Activity in Psoriatic Arthri-
tis (DAPSA), and Composite Psoriatic Disease Activity
Index (CPDAI). Arthritis Care Res (Hoboken) 2011;63 Suppl
11:S64–85.
20. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland
CS, Farrar JT, et al. Interpreting the clinical importance of
treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. J Pain 2008;9:105–21.
21. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh
CA, et al. Remission in psoriatic arthritis: is it possible and
how can it be predicted? Arthritis Res Ther 2010;12:R94.
22. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen
HL, Hetland ML. Predictors of treatment response and drug
continuation in 842 patients with ankylosing spondylitis
treated with anti-tumour necrosis factor: results from 8
1038 van der Heijde et al
years’ surveillance in the Danish nationwide DANBIO regis-
try. Ann Rheum Dis 2010;69:2002–8.
23. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP,
Hyrich KL, et al. Predictors of response to anti-TNF therapy
in ankylosing spondylitis: results from the British Society
for Rheumatology Biologics Register. Rheumatology (Oxford)
2010;49:563–70.
24. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper
J, Kron M, et al. Effectiveness, safety, and predictors of good clin-
ical response in 1250 patients treated with adalimumab for
active ankylosing spondylitis. J Rheumatol 2009;36:801–8.
25. Vastesaeger N, Van Der Heijde D, Inman RD, Wang Y,
Deodhar A, Hsu B, et al. Predicting the outcome of ankylos-
ing spondylitis therapy. Ann Rheum Dis 2011;70:973–81.
26. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F,
Pangan AL. Early response to adalimumab predicts long-
term remission through 5 years of treatment in patients with
ankylosing spondylitis. Ann Rheum Dis 2012;71:700–6.
27. Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J,
Shrom D, et al. Early clinical response as a predictor of sub-
sequent response to ixekizumab treatment: results from a
phase II study of patients with moderate-to-severe plaque
psoriasis. Br J Dermatol 2013;169:1337–41.
28. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R,
Burmester GR, et al. Persistent clinical efficacy and safety of
infliximab in ankylosing spondylitis after 8 years: early clin-
ical response predicts long-term outcome. Rheumatology
(Oxford) 2011;50:1690–9.
29. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka
Y, Eguchi K, et al. Early response to certolizumab pegol pre-
dicts long-term outcomes in patients with active rheumatoid
arthritis: results from the Japanese studies. Mod Rheumatol
2015;25:11–20.
30. Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T, Abe
T, et al. Prediction of clinical response after 1 year of inflixi-
mab therapy in rheumatoid arthritis based on disease activ-
ity at 3 months: posthoc analysis of the RISING study.
J Rheumatol 2015;42:599–607.
31. Curtis JR, Luijtens K, Kavanaugh A. Predicting future
response to certolizumab pegol in rheumatoid arthritis
patients: features at 12 weeks associated with low disease
activity at 1 year. Arthritis Care Res (Hoboken) 2012;64:
658–67.
32. Van der Heijde D, Keystone EC, Curtis JR, Landewe RB,
Schiff MH, Khanna D, et al. Timing and magnitude of initial
change in disease activity score 28 predicts the likelihood
of achieving low disease activity at 1 year in rheumatoid
arthritis patients treated with certolizumab pegol: a post-
hoc analysis of the RAPID 1 trial. J Rheumatol 2012;39:
1326–33.
Axial SpA and PsA Predictability 1039
